Tagged with menarini

Italy Below we present recent news from Italy’s biopharma industry, including the recent acquisition of Stemline Therapeutics by Menarini, research collaboration between Italy and China, labelling regulations, a new biotech sector report and new studies on antibodies against Covid-19.   Menarini gains presence in US oncology market with acquisition of Stemline…

Italy Italy’s pharma industry consistently ranks among the top 10 globally, with domestic companies making up a significant share. These, largely private family-owned firms also have an increasingly global footprint, with international operations now making up a larger portion of their revenues than ever before. See below for the top six…

Italy Menarini Group, the largest Italian pharmaceutical company by turnover, has made its first move into the US oncology market through the acquisition of Stemline Therapeutics.   The deal, said to be worth USD 677 million, was announced on 4 May 2020 and completed on 10 June. The acquisition of Stemline,…

Thailand As the general manager of Menarini Thailand, Thomas Scott Birsinger shares the importance of the Thai affiliate within the company’s operations in the region. He also describes its efforts to work closely with both the government and industry to help ensure access to the most crucial medicines across very diverse…

Turkey Uğur Bingöl, general manager of Ibrahim Etem Menarini, speaks of his company’s rapid growth and new product lines. He also describes his take on the Turkish pharmaceutical market and outlines his strategic priorities to continue growing Ibrahim Etem Menarini’s presence in Turkey.   We are committed to the localization movement…

Pharma The country manager of Berlin-Chemie / A. Menarini Hungary, Dr. Peter Olah, explains the impact of a more targeted sales force in driving the company in the last three years, while highlighting his ambitions to push the affiliate into more specialty care. He also describes the most salient challenges currently…

Menarini Menarini’s Turkish subsidiary, Ibrahim Etem Menarini, has adapted to the current pharmaceutical market and is positioned to grow in several segments including their new OTC business, but is constrained by their current capacity which has minimal excess in some specific lines of production. Uğur Bingöl, the new managing director discusses…

Menarini Austria Dr. Nikitsch, you started Menarini’s Austrian operations almost 13 years ago. Would you say that Menarini’s presence in Austria today reflects the vision you had for the company in Austria at its creation? I would go beyond this statement and say that Menarini Austria is more today than we expected…

market You established Menarini’s Irish affiliate in 1999. How have you seen the market evolve over these last 13 years? The major changes in the market have principally occurred in the last four or five years, rather than the previous ten. Generally speaking, the industry has always had a very strong…

Menarini Pharma Netherlands Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What is the strategic role that the Netherlands and the Dutch market play for Menarini globally? When we started in 1996,…

Menarini After 67 years in the pharmaceutical industry, of which 45 at the head of Menarini, what would you say have been your personal keys to success? Most of my life, I worked three shifts. Meaning arriving at the office at 8:30am, come back home at 1pm, back to work at…

Berlin Chemie/Menarini When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and Central Asia. As the CEO of Berlin Chemie for the last seven years, what would you highlight as the main…